Savara (NASDAQ:SVRA) Sees Strong Trading Volume - Time to Buy?

Key Points

• Savara shares saw unusually high trading activity: 4.79 million shares traded, 170% above average volume, and the stock rose to $5.105 from a prior close of $4.92.
• Analyst views were mostly positive: Seven analysts rated the stock Buy and one Sell, producing a “Moderate Buy” consensus and an average price target of $10.25.
• Savara reported quarterly adjusted earnings per share of -$0.17, slightly better than analysts’ -$0.18 estimate. Its lead candidate, inhaled molgramostim, is being developed for a rare lung disease.

Savara Inc. (NASDAQ:SVRA - Get Free Report) saw unusually-strong trading volume on Wednesday. 4,789,849 shares were traded during mid-day trading, an increase of 170% from the average daily volume of 1,774,836 shares. The stock last traded at $5.1050 and had previously closed at $4.92.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Royal Bank Of Canada set a $10.00 price target on shares of Savara in a research report on Wednesday, October 7th. Weiss Ratings restated a "sell (d-)" rating on shares of Savara in a research report on Thursday, October 15th. JPMorgan Chase & Co. began coverage on Savara in a research note on Wednesday, October 7th. They issued an "overweight" rating and a $12.00 target price on the stock. Citigroup reiterated a "market outperform" rating on shares of Savara in a report on Wednesday, October 7th. Finally, Wall Street Zen cut Savara from a "hold" rating to a "sell" rating in a report on Sunday, October 4th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $10.25.

Savara Stock Performance

The company has a market capitalization of $1.04 billion, a PE ratio of -8.79 and a beta of 0.32. The company has a debt-to-equity ratio of 0.21, a quick ratio of 10.13 and a current ratio of 10.13. The stock's fifty day simple moving average is $4.97 and its 200-day simple moving average is $5.35.

Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported ($0.17) EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.01. As a group, equities analysts predict that Savara Inc. will post -0.66 earnings per share for the current year.

Institutional Trading of Savara

Hedge funds and other institutional investors have recently bought and sold shares of the company. Nan Fung Trinity HK Ltd. raised its holdings in Savara by 1,088.3% in the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 1,842,350 shares of the company's stock valued at $9,507,000 after acquiring an additional 1,687,310 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Savara during the 3rd quarter worth $54,000. Profund Advisors LLC boosted its holdings in shares of Savara by 7.3% during the third quarter. Profund Advisors LLC now owns 49,741 shares of the company's stock worth $257,000 after purchasing an additional 3,370 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Savara by 14.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 37,488 shares of the company's stock worth $190,000 after purchasing an additional 4,874 shares during the last quarter. Finally, Moody Aldrich Partners LLC boosted its holdings in shares of Savara by 4.2% during the third quarter. Moody Aldrich Partners LLC now owns 502,932 shares of the company's stock worth $2,595,000 after purchasing an additional 20,139 shares during the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Savara Company Profile

Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara's lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.